Samsung BioLogics, Bristol Extend Drug-Production Agreement
This article was originally published in PharmAsia News
Executive Summary
Samsung BioLogics and Bristol-Myers Squibb have agreed to extend their partnership that has the South Korea company producing several BMS biologic treatments.